Tacrolimus-eluting nerve guidance conduit for enhanced regeneration in critical-sized peripheral nerve injuries

PROJECT SUMMARY/ABSTRACT
This project aims to commercialize a state-of-the-art FK506-eluting, biodegradable nerve conduit designed to
improve the treatment and outcomes of peripheral nerve injuries dramatically. Peripheral nerve injuries, which
can result from a variety of causes, including accidents and surgical interventions, often lead to significant
disabilities, chronic pain, and a reduction in quality of life for those affected. The limitations of current nerve
repair techniques, such as autografts and synthetic conduits, highlight an urgent need for innovative solutions that
can enhance nerve regeneration and functional recovery.
Our proposal introduces a novel strategy that leverages the regenerative potential of FK506 (tacrolimus), an FDA-
approved immunosuppressant known for its neuroprotective properties, incorporated into a biodegradable
conduit. This conduit is engineered to deliver FK506 directly to the site of nerve injury in a controlled and
sustained manner, optimizing the environment for nerve regeneration.
In Phase II of our FK506-eluting nerve conduit project, we focus on three primary aims: 1) optimizing the
manufacturing process for clinical-grade consistency, 2) validating the conduit’s efficacy in enhanced animal
models to better mirror human nerve injury scenarios, and 3) conducting thorough biocompatibility and safety
assessments to ensure no adverse effects. These steps are crucial for preparing the conduit for clinical trials,
aiming to revolutionize peripheral nerve injury treatment by proving its superiority in promoting nerve
regeneration and functional recovery. Successful completion will pave the way for regulatory submissions and
set the stage for clinical applications, marking a significant leap toward improving patient outcomes in nerve
repair.
This project seeks to revolutionize peripheral nerve injury treatment, improving surgical outcomes and patient
quality of life. It aligns with the National Institutes of Health (NIH) mission to advance biomedical research and
public health by developing innovative solutions to reduce the burden of nerve injuries. The success of this project
could significantly reduce healthcare costs by decreasing the need for repeated surgeries and long-term
rehabilitation, addressing a critical gap in current treatment methodologies.
The introduction of this FK506-eluting nerve conduit represents a significant advancement in regenerative
medicine and nerve repair, potentially setting a new benchmark in therapeutic approaches for peripheral nerve
injuries. Upon successful completion, this project will progress to Phase IIB, focused on scaling up production,
extensive biocompatibility testing, and preparations for clinical trials, ultimately bringing this transformative
technology to patients and clinicians.

Grant Number: 2R42NS112066-02
NIH Institute/Center: NIH
Principal Investigator: AZUR AZAPAGIC